Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 10/2017

01-10-2017 | Evolving Therapies (R Bukowski, Section Editor)

Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics

Authors: Jonathan L. Messerschmidt, Prianka Bhattacharya, Gerald L. Messerschmidt

Published in: Current Oncology Reports | Issue 10/2017

Login to get access

Abstract

Purpose of Review

The knowledge base of malignant cell growth and resulting targets is rapidly increasing every day. Clonal theory is essential to understand the changes required for a cell to become malignant. These changes are then clues to therapeutic intervention strategies. Immune system optimization is a critical piece to find, recognize, and eliminate all cancer cells from the host. Only by administering (1) multiple therapies that counteract the cancer cell’s mutational and externally induced survival traits and (2) by augmenting the immune system to combat immune suppression processes and by enhancing specific tumor trait recognition can cancer begin to be treated with a truly targeted focus.

Recent findings

Since the sequencing of the human genome during the 1990s, steady progress in understanding genetic alterations and gene product functions are being unraveled. In cancer, this is proceeding very fast and demonstrates that genetic mutations occur very rapidly to allow for selection of survival traits within various cancer clones. Hundreds of mutations have been identified in single individual cancers, but spread across many clones in the patient’s body. Precision oncology will require accurate measurement of these cancer survival-benefiting mutations to develop strategies for effective therapy. Inhibiting these cellular mechanisms is a first step, but these malignant cells need to be eliminated by the host’s mechanisms, which we are learning to direct more specifically.

Summary

Cancer is one of the most complicated cellular aberrations humans have encountered. Rapidly developing significant survival traits require prompt, repeated, and total body measurements of these attributes to effectively develop multi-agent treatment of the individual’s malignancy. Focused drug development to inhibit these beneficial mutations is critical to slowing cancer cell growth and, perhaps, triggering apoptosis. In many cases, activation and targeting of the immune system to kill the remaining malignant cells is essential to a cure.
Literature
1.
• Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8. This is the landmark paper that describes the clonal theory of cancer. CrossRefPubMed
2.
• Ludmil BA, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. This paper describes the whole genome sequencing of ~7,000 tumor samples and finding701 mutations on average. CrossRef
3.
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. In: Arnold J. Levine and David Lane, editors, additional perspectives on the p53 family. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. doi:10.​1101/​cshperspect.​a001008. This chapter presents the location of p53 mutations in coding, non-coding and salient regions of the genes, including promotors. This suggests that malignancy could result for mutations in any portion of a gene sequence, not just the protein coded area. CrossRefPubMedPubMedCentral
4.
• Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6(12):924–35. This review builds on the “evolutionary” aspects of cancer development. CrossRefPubMed
5.
• Pepper JW, Findlay S, Kassen R, Spencer SL, Maley CC. Cancer research meets evolutionary biology. Evol Appl. 2009;2(1):62–70. This review builds on the “evolutionary” aspects of cancer development. CrossRefPubMedPubMedCentral
6.
• Messerschmidt JL, Pendergast GC, Messerschmidt GL. How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: helping nonimmunologists decipher recent advances. Oncologist. 2016;21:1–11. This review builds describes normal and abnormal immune system function and coins the term Darwinian “revolution”. CrossRef
7.
• Greaves M, editor. Cancer: the evolutionary legacy. New York: Oxford University Press; 2000. This chapter presents Darwinian evolution for cancer through random mutations and sets the stage for the clonal theory acceptance as truth.
8.
• Schreiber RD, Old LJ, Smyth ML. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70. The landmark paper describes the 3 major immune actions following cancer formation leading to death, equilibrium and immune escape. CrossRefPubMed
9.
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–24.CrossRefPubMed
10.
Tan M, Quintal L. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. J Clin Pharm Ther. 2015;40(5):504–7.CrossRef
11.
12.
13.
14.
15.
Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, Vogelstein B, et al. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A. 2001;98(10):5770–5.CrossRefPubMedPubMedCentral
16.
Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol. 1999;9(12):M57–60.CrossRefPubMed
17.
Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment—tumorigenesis and therapy. Nat Rev Cancer. 2005;5(11):867–75.CrossRefPubMed
18.
Siegmund KD, Marjoram P, Woo Y-JJ, Tavaré S, Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci U S A. 2009;106(12):4828–33.CrossRefPubMedPubMedCentral
19.
• Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–13. The paper describes the data supporting the clonal theory of Newall and forms the basis of today’s understanding of the cancer clonal theory. CrossRefPubMedPubMedCentral
20.
21.
Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9(4):302–12.CrossRefPubMed
22.
Tubiana M, Malaise EP, Chavaudra N. The relationship between growth rate, labelling index and histological type of human solid tumours. Eur J Cancer. 1973;9(4):305–12.CrossRefPubMed
23.
Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356–61.CrossRefPubMed
24.
25.
Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319–25.CrossRefPubMed
26.
Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82.CrossRefPubMed
27.
28.
• Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332–6. The paper describes for the first time the clonagenic theory in myeloma cell as reality. CrossRefPubMed
29.
Calame KL. Plasma cells: finding new light at the end of b cell development. Nat Immunol. 2001;2(12):1103–8.CrossRefPubMed
30.
• Tang M, Zhao R, van de Velde H, et al. Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clin Cancer Res. 2016;22(16):4206–14. The paper describes that chemotherapy can “select” for prior mutated resistant (passenger) changes that become important when selections pressures are applied. CrossRefPubMedPubMedCentral
31.
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98.CrossRefPubMed
32.
San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMed
33.
34.
• Burger JA, Landau DA, Amaro TW, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589. The paper describes/confirms that chemotherapy can “select” for prior mutated resistant (passenger) changes that become important when selections pressures are applied. CrossRefPubMedPubMedCentral
35.
Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–80.CrossRefPubMedPubMedCentral
36.
37.
Woyach JA, Furman RR, Liu T-MM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–94.CrossRefPubMedPubMedCentral
38.
39.
•• Braxton DR, Zhang R, Morrissette JD, Loaiza-Bonilla A, Furth EE. Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic sub-groups with differing patterns of genetic evolution. Int J Cancer. 2016;139(7):1546–56. The paper describes differing patterns can select for prior mutated resistant changes that become important when selections pressures are applied. CrossRefPubMed
40.
Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26–38.CrossRefPubMedPubMedCentral
41.
Camacho E, Hernández L, Hernández S, et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood. 2002;99(1):238–44.CrossRefPubMed
42.
Wu C, de Miranda NF, Chen L, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget. 2016;7(25):38180–90.CrossRefPubMedPubMedCentral
43.
Pelosi G, Pellegrinelli A, Fabbri A, et al. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016;488(6):651–62.CrossRef
44.
Hardiman KM, Ulintz PJ, Kuick RD, et al. Intra-tumor genetic heterogeneity in rectal cancer. Lab Investig. 2016;96(1):4–15.CrossRefPubMed
45.
46.
47.
48.
• Kataoka K, Shiraishi Y, Takeda Y. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature. 2016;534:402–6. The paper describes genomic changes that select resistant clones via PD-L1 expression. CrossRefPubMed
49.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–95.PubMedPubMedCentral
50.
Nishimura H, Agata Y, Kawasaki A, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol. 1996;8:773–80.CrossRefPubMed
51.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.CrossRefPubMed
52.
Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538–45.CrossRefPubMed
53.
Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding. Eur J Immunol. 2007;37(9):2405–10.CrossRefPubMed
54.
Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–53.CrossRefPubMedPubMedCentral
55.
Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002;32:666–9.CrossRefPubMed
56.
Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111:363–70.CrossRefPubMedPubMedCentral
57.
Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501–5.PubMed
58.
Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109:1499–505.CrossRefPubMed
59.
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on nonsmall cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.CrossRefPubMed
60.
Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151–7.CrossRefPubMed
61.
Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174–9.CrossRefPubMedPubMedCentral
62.
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62.CrossRefPubMedPubMedCentral
63.
Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–10.CrossRefPubMedPubMedCentral
64.
Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296–304.CrossRefPubMed
65.
Chemnitz JM, Eggle D, Driesen J, et al. RNA-fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4+ T cells in Hodgkin’s lymphoma. Blood. 2007;110:3226–33.CrossRefPubMed
66.
Shimauchi T, Kabashima K, Nakashima D, et al. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Int J Cancer. 2007;121:2585–90.CrossRefPubMed
67.
Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17:133–44.CrossRefPubMed
68.
Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol. 2005;174:3408–15.CrossRefPubMed
69.
Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;2006(177):5928–35.CrossRef
70.
Okazaki T, Honjo T. PD-1 and PD-1 ligands from discovery to clinical application. Int Immunnol. 2007;19:813–24.CrossRef
71.
72.
Finger EB, Bluestone JA. When ligand becomes receptor—tolerance via B7 signaling on DCs. Nat Immunol. 2002;3:1056–7.CrossRefPubMed
73.
Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTAL-4-Fc in human CD4+ T cells. Blood. 2005;105:1574–81.CrossRefPubMed
74.
Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.CrossRefPubMed
75.
Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002;101:151–5.CrossRefPubMed
76.
Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74.CrossRefPubMed
77.
Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1 deficient mice. J Exp Med. 2000;191:891–8.CrossRefPubMedPubMedCentral
78.
Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29.CrossRefPubMedPubMedCentral
79.
80.
81.
• Terme M, Ulrich E, Aymeric I, et al. IL-18 induces PD-1dependent immunosuppression in cancer. Cancer Res. 2011;71:5393–9. The paper describes how the immune system can induce immune resistance responses by tissues in the local environment of immune reactions. CrossRefPubMed
82.
83.
Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumora T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.CrossRefPubMed
84.
Webster WS, Lohse CM, Thompson RH, et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 2006;107:46053.CrossRef
85.
Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–66.CrossRefPubMed
86.
Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports and adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.CrossRefPubMedPubMedCentral
87.
• Kumar V, Patel S, Tcyganov E, Gabrilovich D. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–20. The review describes the roles of myeloid-derived suppressor cells and their various local functions to suppress an ongoing immune reaction. CrossRefPubMedPubMedCentral
Metadata
Title
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics
Authors
Jonathan L. Messerschmidt
Prianka Bhattacharya
Gerald L. Messerschmidt
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Oncology Reports / Issue 10/2017
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0625-2

Other articles of this Issue 10/2017

Current Oncology Reports 10/2017 Go to the issue

Integrative Care (C Lammersfeld, Section Editor)

Mind-Body Therapies in Cancer: What Is the Latest Evidence?

Breast Cancer (B Overmoyer, Section Editor)

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1

Head and Neck Cancers (EY Hanna, Section Editor)

Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Cardio-oncology (EH Yang, Section Editor)

Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity

Geriatric Oncology (AR MacKenzie, Section Editor)

Motivating Older Adults with Cancer to Keep Moving: the Implications of Lifestyle Interventions on Physical Activity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits